SK Life Science, the U.S. subsidiary of SK biopharmaceuticals, said Tuesday that it will host a symposium and present updated research on cenobamate, a treatment for partial-onset seizures, at the 2024 American Epilepsy Society (AES) Annual Meeting in Los Angeles from Dec. 6 to 10.

The symposium, scheduled for Dec. 6 at 6 p.m. at the JW Marriott Los Angeles L.A. Live, will focus on "prioritizing seizure management through real-world case studies," addressing the impact of persistent seizures on treatment outcomes and the unmet need for achieving seizure freedom.

Speakers at the event include David Vossler, professor of neurology at the University of Washington Valley Medical Center; Danielle Becker, professor of neurology and director of epilepsy at Ohio State University Wexner Medical Center; and Mohamad Koubeissi, professor and director of the Epilepsy Center at George Washington University.

SK Life Science will present nine poster presentations featuring clinical trial data from Korea, China, and Japan supporting cenobamate’s launch in Asia. Topics include the drug’s efficacy and safety in Asian patients, its effects on epilepsy subtypes, and analyses of maintenance dosage ranges. Additional research will explore the prevalence of arrhythmias in epilepsy patients using medication.

“The pursuit of seizure is a critical and often elusive goal for epilepsy patients,” said Louis Ferrari, vice president of medical affairs at SK Life Science. “Our data presentations this year aim to provide healthcare providers with updated strategies and evidence to better address the needs of their patients.”